Greg Williams is internationally recognised as an experienced litigation lawyer with particular expertise in the conduct of class actions and product liability litigation.

Greg's experience ranges from acting in large-scale class actions for the pharmaceutical and banking industries to advising on regulatory issues, investigations advertising and labelling requirements, and managing product safety issues and recalls.

Greg has particular experience in acting for clients operating in the pharmaceutical and medical devices industries where his science qualifications and laboratory experience give him a special insight into and understanding of his clients' commercial imperatives and legal needs.

Read More

Expertise

Expand all

Class Actions

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): In one of the largest product liability class actions in the Asia-Pacific, Clayton Utz represented Merck & Co Inc and Merck Sharp & Dohme (MSD) Australia Limited in the defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor.  On 11 May 2012, we secured an historic High Court win in these proceedings.  Greg acted as junior counsel at the three month long first instance trial.

Storm Financial: Greg acted for Commonwealth Bank of Australia in its defence of a class action brought by former clients of Storm Financial in the Queensland Registry of the Federal Court.  Greg led the defence team through an eight month trial encompassing more than 60 sitting days.  The matter ultimately settled before judgment was handed down.

VW Emissions: Greg is currently defending various members of the VW Group in class actions brought on behalf of vehicle owners in respect of diesel emissions issues.  There are five class actions which are being managed simultaneously in the NSW Registry of the Federal Court.

Dust Diseases Tribunal of NSW: Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.

DSS: Provided strategic advice to DSS in their defence of class action proceedings brought in respect of the alleged discriminatory application of the BSWAT.

Airbus: Greg has acted for companies in the Airbus group in Australian litigation arising from the uncontained engine failure of QF32 in 2010

Personal Injury Litigation: Greg had appeared for and advised defendants in personal injury claims ranging from product liability, through industrial accidents, motor vehicle collisions and aircraft accidents.

See Class Actions

Product Liability

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Gravigard (Copper 7) intrauterine contraceptive device (IUD):
 Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

CBA - Financial Advice: Advising CBA in relation to the establishment and conduct of its Advice Review Program.  The program involves CBA reviewing financial advice it has previously provided to Customers and making them offers of compensation for inappropriate advice, is the largest program of its kind in Australia.

Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): In one of the largest product liability class actions in the Asia-Pacific, Clayton Utz represented Merck & Co Inc and Merck Sharp & Dohme (MSD) Australia Limited in the defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor.  On 11 May 2012, we secured an historic High Court win in these proceedings.  Greg acted as junior counsel at the three month long first instance trial.

Airbus: Greg has acted for companies in the Airbus group in Australian litigation arising from the uncontained engine failure of QF32 in 2010

Personal Injury Litigation: Greg had appeared for and advised defendants in personal injury claims ranging from product liability, through industrial accidents, motor vehicle collisions and aircraft accidents. 

See Product Liability

Litigation and Dispute Resolution

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Storm Financial: Greg acted for Commonwealth Bank of Australia in its defence of a class action brought by former clients of Storm Financial in the Queensland Registry of the Federal Court.  Greg led the defence team through an eight month trial encompassing more than 60 sitting days.  The matter ultimately settled before judgment was handed down.

CBA - Financial Advice: Advising CBA in relation to the establishment and conduct of its Advice Review Program.  The program involves CBA reviewing financial advice it has previously provided to Customers and making them offers of compensation for inappropriate advice, is the largest program of its kind in Australia. 

Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Dust Diseases Tribunal of NSW:
 Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.

Pharmaceutical company: Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.

 

Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): In one of the largest product liability class actions in the Asia-Pacific, Clayton Utz represented Merck & Co Inc and Merck Sharp & Dohme (MSD) Australia Limited in the defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor.  On 11 May 2012, we secured an historic High Court win in these proceedings.  Greg acted as junior counsel at the three month long first instance trial. 

VW Emissions: Greg is currently defending various members of the VW Group in class actions brought on behalf of vehicle owners in respect of diesel emissions issues.  There are five class actions which are being managed simultaneously in the NSW Registry of the Federal Court. 


See Litigation and Dispute Resolution

Pharmaceutical and Medical Devices

Pharmaceutical Benefits Scheme: Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.

Pharmaceutical company: Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.

Roche Products Pty Ltd: Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Relationships with Healthcare Professionals: Greg has assisted international device manufacturers with physician engagement in Australia, including advice in relation to fellowship arrangements and speaker and consultant agreements.

DHS (formerly Medicare Services Advisory Committee) and the Prostheses & Devices Committee: assisting clients in their negotiations with the Medicare Services Advisory Committee and the Prostheses & Devices Committee and advising in relation to the rights of review and appeal from decisions of those Committees.

Advertising Disputes: Greg has acted for medical device companies in advertising disputes, including disputes with competitors referred to relevant industry dispute resolution Tribunals and complaints to the TGA's Complaints Resolution Panel. 

Engagement with Regulators: Greg has worked with a number of medical device companies on their engagement with regulators.  This work has included: providing advice about Australia's medical device classification rules, assisting to prepare submissions to the TGA on a range of issues, including enforcement actions and applications to amend indications and assisting a company to respond to allegations by the Australian Health Practitioner Regulation Agency that it was improperly influencing health practitioner's patient care. 

Pharmaceutical Pricing Issues: advices numerous pharmaceutical clients in relation to strategy for and legal issues arising from their dealings with the Pharmaceutical Benefits Division and Pharmaceutical Benefits Advisory Committee, bodies responsible for the reimbursement arrangements for pharmaceutical products in Australia. This has included advice about the effects of biosimilarity on the reimbursement of originator pharmaceuticals.

See Pharmaceutical and Medical Devices

Healthcare and Life Sciences

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Dust Diseases Tribunal of NSW: Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.

Pharmaceutical Benefits Scheme: Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.

Pharmaceutical company: Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.

Roche Products Pty Ltd: Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Relationships with Healthcare Professionals: Greg has assisted international device manufacturers with physician engagement in Australia, including advice in relation to fellowship arrangements and speaker and consultant agreements.

DHS (formerly Medicare Services Advisory Committee) and the Prostheses & Devices Committee: assisting clients in their negotiations with the Medicare Services Advisory Committee and the Prostheses & Devices Committee and advising in relation to the rights of review and appeal from decisions of those Committees.

Advertising Disputes: Greg has acted for medical device companies in advertising disputes, including disputes with competitors referred to relevant industry dispute resolution Tribunals and complaints to the TGA's Complaints Resolution Panel. 

Engagement with Regulators: Greg has worked with a number of medical device companies on their engagement with regulators.  This work has included: providing advice about Australia's medical device classification rules, assisting to prepare submissions to the TGA on a range of issues, including enforcement actions and applications to amend indications and assisting a company to respond to allegations by the Australian Health Practitioner Regulation Agency that it was improperly influencing health practitioner's patient care.

Pharmaceutical Pricing Issues: advices numerous pharmaceutical clients in relation to strategy for and legal issues arising from their dealings with the Pharmaceutical Benefits Division and Pharmaceutical Benefits Advisory Committee, bodies responsible for the reimbursement arrangements for pharmaceutical products in Australia. This has included advice about the effects of biosimilarity on the reimbursement of originator pharmaceuticals.


Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.

See Healthcare and Life Sciences

White Collar Crime and Investigations

Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.

See White Collar Crime and Investigations

Investigations and Crisis Management

Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint. 

See Investigations and Crisis Management

Knowledge

    Related knowledge information is loading